Alpha Cancer Technologies

Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with products under development in oncology and auto-immune disease indications. The company’s drug products use our proprietary recombinant human alpha fetoprotein (AFP) with unique immuno-oncology properties.

Alpha Fetoprotein (AFP) is a human protein produced by the embryo during fetal development and serves two critical functions: a) picks up nutrients from the mother and delivers them to the embryo; and b) normalizes immune system responses so the mother’s immune cells don’t attack the embryo.

ACT has exclusive worldwide rights to the targeted delivery platform Alpha Fetoprotein with over $100 million spent on the development of the in-licensed technology. Clinical studies of AFP have demonstrated safety in over 300 patients and established a robust Drug Master file with the FDA including manufacturing, toxicology, and human safety.

Management Team

Richard Potts

Chairman
rpotts@alpha-cancer.com 416-464-2768 416-946-1515

Demonstrated a rich blend of leadership roles with a track record of management, finance and marketing of growth companies across a diverse spectrum of industries, including biotechnology, medical and information technology. Mr. Potts has co-founded, established strategic plans, secured multi-million dollars in financing, public listings and facilitated partnerships as a founder, owner and executive in numerous companies in the knowledge-based industry.

Dr. Igor Sherman

President and CEO
isherman@alpha-cancer.com 416-826-6626 416-782-3944

Extensive experience and expertise in the pharmaceutical and biotechnology industries, particularly in oncology. Prior to ACT, Dr. Sherman was Director of Clinical Research and Director of Scientific Affairs for YM Biosciences Inc., where he was responsible for preclinical and clinical development, as well as registration strategies for all oncology and pain products in YM Biosciences’ portfolio. Dr. Sherman was also Scientific Director of Oncology for AstraZeneca Canada Inc.

Dianne Parsons (CA)

CFO

Jeffrey Puritt

Board Member

Mr. Jeffrey D. Puritt serves as the President of TELUS International, Inc. Mr. Puritt has been Senior Vice President of TELUS Communications Inc. since 2008. Mr. Puritt has wealth of international experience in communications and technology sectors including mergers, acquisitions, divestitures, strategic planning, corporate reorganizations and asset and contract management.

Borys Chabursky

Board Member

Borys Chabursky founded Shift Health to develop convergent solutions that improve human health and wellbeing. With Borys’ oversight, Shift Health has successfully delivered over 500 life sciences assignments for more than 300 clients in North America, Europe and the Middle East.

Borys is a member of the advisory boards of GEMMA Biotechnology, Mineara Alamos Inc. and Temperance Capital. He is also a member of the Young Presidents’ Organization (YPO) and a board member of the Maple Leaf Chapter (Greater Toronto Chapter).

Christopher W. Morgan

Board Member

Christopher Morgan is a Partner at Skadden, a firm specializing in U.S. law in Canada. He is a trusted adviser to many of Canada’s business and financial leaders as well as a thought leader in the Canada / U.S. cross border transactions space.

Mr. Morgan lectures on cross-border securities law topics and repeatedly has been selected for inclusion in The Best Lawyers in Canada for corporate law and Who’s Who Legal for Capital Markets.

Head Office

Alpha Cancer Technologies
MaRs Centre - South Tower
200-101 College St.
Toronto, Ontario, M5G 1L7
Canada